Table 6Varying the time horizon showing different incremental cost-effectiveness ratio (ICER) per QALY

No NIV and NIVICER per QALYICER per life year
Time horizon (years)
2£42,532.93£36,422.42
3£34,639.00£24,976.42
4£31,999.84£21,350.60
5£31,148.44£20,040.57
Standard and NIV (years)
2£25,349.91£21,708.00
3£21,556.38£15,543.21
4£20,704.26£13,814.08
5£20,665.69£13,296.08

From: Appendix 9.7, Health economic evaluation

Cover of Motor Neurone Disease
Motor Neurone Disease: The Use of Non-Invasive Ventilation in the Management of Motor Neurone Disease [Internet].
NICE Clinical Guidelines, No. 105.
Centre for Clinical Practice at NICE (UK).
Copyright © 2010, National Institute for Health and Clinical Excellence.

All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.